

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67

August 18, 2025

ISSUE No.
1735

IN THIS ISSUE

In Brief: Pruritus Following Antihistamine Discontinuationp 135

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67 (Issue 1735)

August 18, 2025

Take CME Exams

IN BRIEF

Pruritus Following Antihistamine Discontinuation

The FDA is requiring a new warning in the prescription and over-the-counter labels of the oral second-generation H₁-antihistamines cetirizine (*Zyrtec*, and others) and levocetirizine (*Xyzal*, and others) about the risk of severe pruritus following discontinuation of treatment.¹

Cases reported to the FDA Adverse Events Reporting System were rare (209 worldwide reports over >6 years), but many of them described severe pruritus requiring medical intervention that occurred within a few days of stopping cetirizine or levocetirizine. Most cases occurred after more than 3 months of daily use, but some occurred after less than one month. The mechanism of the effect is unknown.

Restarting the antihistamine improved pruritus symptoms in most patients; subsequently tapering off the drug resolved symptoms in some of these patients.

Whether switching to another antihistamine, such as loratadine (*Claritin*, and others) or fexofenadine (*Allegra*, and others), would prevent or improve pruritus or whether these drugs could carry a similar risk after their discontinuation is unknown. Some expert clinicians have prescribed (off-label) the interleukin-4 receptor alpha antagonist dupilumab (*Dupixent*) or the recombinant anti-IgE monoclonal antibody omalizumab (*Xolair*, and biosimilar), both of which are FDA-approved for treatment of chronic spontaneous urticaria,^{2,3} for treatment of patients whose symptoms persist following taper and discontinuation of cetirizine or levocetirizine. ■

1. FDA Drug Safety Communication. FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names). May 16, 2025. Available at: <https://bit.ly/4kelrKz>. Accessed July 30, 2025.
2. In brief: Dupilumab (Dupixent) for chronic spontaneous urticaria. *Med Lett Drugs Ther* 2025; 67:111.
3. Omalizumab (Xolair) for chronic urticaria. *Med Lett Drugs Ther* 2013; 55:43.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:



Copyright 2025. ISSN 1523-2859

The
Medical
Letter